Recurrence of malignant brain tumors results in a poor prognosis with limited treatment options. High-dose chemotherapy with autologous hematopoietic cell rescue (AHCR) has been used in patients with recurrent malignant brain tumors and has shown improved outcomes compared with standard chemotherapy. Temozolomide is standard therapy for glioblastoma and has also shown activity in patients with medulloblastoma/primitive neuro-ectodermal tumor (PNET), particularly those with recurrent disease. Temozolomide was administered twice daily on days − 10 to − 6, followed by thiotepa 300 mg/m 2 per day and carboplatin dosed using the Calvert formula or body surface area on days − 5 to − 3, with AHCR day 0. Twenty-seven patients aged 3-46 years were enrolled. Diagnoses included high-grade glioma (n = 12); medulloblastoma/PNET (n = 9); central nervous system (CNS) germ cell tumor (n = 4); ependymoma (n = 1) and spinal cord PNET (n = 1). Temozolomide doses ranged from 100 mg/m 2 per day to 400 mg/m 2 per day. There were no toxic deaths. Prolonged survival was noted in several patients including those with recurrent high-grade glioma, medulloblastoma and CNS germ cell tumor. Increased doses of temozolomide are feasible with AHCR. A phase II study using temozolomide, carboplatin and thiotepa with AHCR for children with recurrent malignant brain tumors is being conducted through the Pediatric Blood and Marrow Transplant Consortium. 1 There are however large variations depending on tumor histology and age of the patient but regardless of initial histology, once a CNS tumor recurs the prognosis is dismal with limited treatment options, particularly for those who have already received radiotherapy. The use of standard dose chemotherapy can produce objective radiographic responses but these responses are invariably short lived.
INTRODUCTION
Despite advances in surgery, radiotherapy and chemotherapy the survival rates for malignant brain tumors have not improved significantly over the last 50 years, with an estimated 5-year survival rate of 34%. 1 There are however large variations depending on tumor histology and age of the patient but regardless of initial histology, once a CNS tumor recurs the prognosis is dismal with limited treatment options, particularly for those who have already received radiotherapy. The use of standard dose chemotherapy can produce objective radiographic responses but these responses are invariably short lived. 2, 3 High-dose, myeloablative chemotherapy with AHCR is frequently adopted in an attempt to improve the dismal survival rates in these patients and has shown improved outcomes when compared with standard chemotherapy treatment. 4, 5 Dunkel et al. 4 evaluated the use of high-dose carboplatin, thiotepa and etoposide with AHCR in adults and children with recurrent medulloblastoma, reporting event-free survivals of 34% at 3 years. Finlay et al. 5 demonstrated that pediatric patients with recurrent malignant astrocytomas and minimal disease treated with thiotepa and etoposide-based chemotherapy regimens and AHCR had 4-year survival estimates of 46% compared with 0% for those treated with conventional chemotherapy. Of note, in the study by Finlay et al. 5 differences in distributions of survival were not significant when stratified by surgical debulking. However, for patients who were surgically debulked, the survival distributions were significantly different. This evidence suggests that these regimens are more efficacious in patients with minimal residual tumor burden at the time of high-dose chemotherapy.
Temozolomide is an oral alkylating chemotherapeutic agent that when coupled with irradiation, is now the standard of care for newly diagnosed glioblastoma in adults and also demonstrates antitumor activity as a single agent in the treatment of recurrent glioma. 6 Temozolomide has also shown some activity in pediatric brain tumors in numerous phase I and II trials. [7] [8] [9] [10] [11] When used in patients with medulloblastoma/PNET, particularly patients with recurrent disease that were heavily pre-treated, it has also been shown to be effective. 12 The drug is stable at low pH, is completely absorbed after oral administration, and rapidly penetrates the CNS, making it an ideal candidate for study in patients with CNS tumors. 9 When administered daily at 200 mg/m 2 for 5 days every 28 days, temozolomide showed a tolerable toxicity profile in children, with myelosuppression being the most common side-effect reported. 9, 13 The current study builds upon prior research with high-dose chemotherapy and AHCR 4, [14] [15] [16] [17] [18] [19] [20] with the addition of temozolomide in place of etoposide. 4, 15 The primary objective of this study was to define the maximum tolerated dose (MTD) of temozolomide administered twice daily in combination with myeloablative 1 doses of thiotepa and carboplatin with AHCR in patients with either recurrent high-grade brain tumors with minimal residual disease or those with newly diagnosed brain tumors with minimal residual disease following conventional therapy.
MATERIALS AND METHODS Patients
Patients between one and 50 years of age with malignant brain tumors that were recurrent or demonstrated resistance to conventional therapies and who had not been previously exposed to myeloablative doses of thiotepa were deemed eligible for this study. Characteristics of the patients are summarized in Table 1 . Young children with newly diagnosed malignant brain tumors who achieved minimal disease following standard dose chemotherapy were also eligible. Additional eligibility factors included; Karnofsky Performance Status or Lansky Performance score ⩾ 70%; life expectancy of at least 12 weeks; adequate laboratory values including absolute neutrophil count ⩾ 1.5 × 10 9 /L, platelet count ⩾ 100 × 10 9 /L hemoglobin ⩾ 10 gm/dL, BUN and serum creatinineo 1.5 times the upper limit of normal, total serum bilirubino1.5 times the upper limit of normal, liver enzymeso 2.5 times the upper limit of normal, ejection fraction450% or shortening fraction427%. Patients also had to have an adequate number of autologous hematopoietic cells available, defined as a minimum of 2 × 10 6 CD34+ cells/kg and preferably at least 5 × 10 6 CD34+ cells/kg. In addition, an interval of at least 6 weeks from radiotherapy and at least 4 weeks from chemotherapy was necessary before entering the study. Corticosteroids were permitted up to study entry. Parents or legal guardians gave written informed consent as part of an institutional review board approved protocol.
Patients first underwent collection of autologous peripheral blood hematopoietic progenitor cells following mobilization with filgrastim with or without chemotherapy as per the treating physician's choice. Cytoreductive therapy began after adequate numbers of hematopoietic cells had been collected.
Temozolomide was administered orally, every 12 h for 5 days on days − 10 through − 6. Dosing was based on body surface area except in patientso 3 years of age where dosing was based upon body weight. All doses were rounded off to the nearest 5 mg to accommodate capsule strength. There was no intra-patient dose escalation. Dose escalation occurred in groups of three: if none of the first three patients at a dose level experienced dose-limiting toxicity (DLT), subsequent patients were to be enrolled at the next higher dose level. If two or three of the first three patients experienced DLT, then that dose was considered to be too high, and the dose was to be decreased to the previous level. If DLT occurred in one of three patients, three additional patients were to be enrolled at that level. If one of six patients experienced DLT, the dose could be escalated. If two or more experienced DLT, the MTD was exceeded. The MTD was defined as one level below the level at which two or more of six patients developed DLT. The following dose levels were studied: 50, 75, 100, 125, 150, 175, 200 mg/m 2 twice daily for 5 consecutive days. Thiotepa 300 mg/m 2 per day was infused intravenously over 3 h daily for 3 days beginning at day − 5. For patients aged o3 years the dose of thiotepa was 10 mg/kg per day. Patients who were obese had their doses based on adjusted weight. Carboplatin was infused intravenously over 4 h following the thiotepa daily for 3 days beginning at day − 5. The dose of carboplatin was calculated using both the Calvert formula 21 to a target of 7 mg/mL/min and body surface area (500 mg/m 2 or 16.7 mg/kg for childreno3 years) and the lower of the two was used. Doses were adjusted daily as needed, based on creatinine clearance results measured before each dose of carboplatin. On day 0,~72 h after completion of the chemotherapy, the cryopreserved autologous hematopoeitic progenitor cells were rapidly thawed and reinfused. Filgrastim was subsequently given daily starting on day +1 until there was evidence of neutrophil engraftment. Antibacterial, antiviral and antifungal agents were administered as per institution guidelines.
Definition of DLT
Primary end points for temozolomide dose escalation included the following toxicities: toxic death, which was defined as death not predominately attributable to progressive disease; veno-occlusive disease (at least two of the following: total bilirubin 48 mg/dL, weight gain410%, liver enlargement or pain in the absence of another cause for these findings); Grade IV renal toxicity; mucositis requiring intubation; and grade IV neurotoxicity.
Evaluation of response
Tumor size was evaluated on enhanced MRI with gadolinium using the MacDonald criteria. The following categories were used: (1) continuing complete response was defined as the continuing absence of radiographically identifiable tumor on comparison scans, (2) complete response was defined as the complete disappearance of all known disease by MRI, (3) partial response was defined as a 450% decrease in tumor size demonstrable by MRI, (4) stable disease (SD) was defined as o50% decrease or no reduction in tumor size demonstrable by MRI, or tumor growth which is less than the criteria defined as progressive disease (5) progressive disease was defined as disease in previously uninvolved areas or after achieving a complete response; clinical or radiological evidence of increased volume of 425% in tumor area with maximum perpendicular diameters in any site of residual disease as compared with Abbreviations: CR = complete response; CNS = central nervous system; NET = neuro-ectodermal tumor; PNET = primitive neuro-ectodermal tumor. Abbreviation: CNS = central nervous system.
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immediate pre study area. Head MRI was performed on day 42, 3 months post AHCR, and every 3 months thereafter until 2 years from AHCR; then 4 months for 1 year, then every 6 months for 1 year and annually thereafter.
RESULTS

Patient characteristics
Twenty-seven patients (18 male; 9 female) aged 3-46 years were enrolled between November 2000 and October 2004 with a median age of 28 years (range 3-49 years). Diagnoses included high-grade glioma (n = 12), medulloblastoma/PNET (n = 9), CNS germ cell tumor (n = 4), ependymoma (n = 1) and spinal cord PNET (n = 1).
Toxicity
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria Version 3.0. Temozolomide doses ranged from 50 mg/m 2 twice daily (100 mg/m 2 per day) to 200 mg/m 2 twice daily (400 mg/m 2 per day) for 5 days. All patients developed pancytopenia which was expected and not listed as a DLT. Significant non-myelosuppressive toxicity developed in less than half of all patients treated. The most common nonmyelosuppressive toxicities included nausea or vomiting (n = 8), elevated transaminases (n = 7) and decrease in performance status (n = 7; see Table 2 ). Eleven patients developed bacteremia (n = 11), whereas four patients developed C. difficile enteritis (n = 4). Two patients developed veno-occlusive disease of the liver (n = 2). The DTLs at 200 mg/m 2 twice daily included grade IV neurotoxicity (n = 1) and severe mucositis (n = 1) subsequently resulting in decrease of the dose to 175 mg/m 2 twice daily (350 mg/m 2 per day). There were no toxic deaths. The median time to recovery of granulocytes (neutrophils4500/mm 3 ) was 10 days. The median time to recovery of platelets (450 000/mm 3 ) was 21 days. The median length of hospital stay for patients was 29 days.
Response Fourteen of 27 patients survived longer than 24 months from study entry (6 out of 12 patients with high-grade glioma (n = 6), 4 out of 9 patients with medulloblastoma/PNET (n = 4), 3 out of 4 patients with CNS germ cell tumor (n = 3) and 1 patient with spinal cord PNET (n = 1)). As of July 2014, 3 patients remain alive after AHCR; 1 patient with medulloblastoma alive 13.5 years from study entry, 2 patients with CNS germ cell tumors alive 13.4 years and 11.5 years from study entry, respectively.
DISCUSSION
Treatment of malignant CNS tumors, particularly patients with high-risk histological types and recurrent and refractory tumors, continues to represent a major challenge. The use of high-dose chemotherapy with AHCR in the treatment of recurrent malignant brain tumors has been investigated with promising responses observed in patients with recurrent medulloblastoma, PNET, highgrade glioma and primary CNS germ cell tumors. 4, 5, 18 It has also been employed in very young children 19, 20, 22, 23 in an attempt to avoid the deleterious long-term consequences of radiotherapy. 24 Previously successful myeloablative regimes often involved combinations of thiotepa, etoposide, carboplatin, carmustine and topotecan. 4, 5, 15, 20, 23, 25 Thiotepa is an important component of high-dose chemotherapy owing to its steep dose-response and evidence that thiotepa is non-cross resistant with other alkylating agents such as cyclophosphamide and melphelan. 26, 27 In the past, combinations of a number of these agents have resulted in high levels of toxicity including mucositis, microvascular damage and acute neurological dysfunction. 26 Toxic death rates were initially as high as 35% in early studies, with more recent studies demonstrating a decline in mortality rate to o 10% 28 which can largely be attributed to improved supportive care. Life-threatening toxicities appear to be more frequent in heavily pre-treated patients.
In this phase I trial, temozolomide was administered in place of etoposide in view of its history of improved outcomes in adult patients with recurrent brain tumors, 6 its synergistic antitumor effects and its ease of administration, which have the potential to improve quality of life and possibly decrease length of hospital stay and costs associated with drug administration. In previous studies it has been shown to have a well-tolerated toxicity profile, with myelosuppression cited as the most common toxicity, followed less commonly by nausea/vomiting, 12 elevated transaminases and hyperbilirubinemia. 11 This study was designed to establish the MTD of temozolomide administered twice daily in combination with myeloablative doses of thiotepa and carboplatin with AHCR in patients with either recurrent malignant brain tumors with MRD or young children newly diagnosed with malignant brain tumors with MRD following standard dose chemotherapy. The recommended phase II dose of temozolomide was determined to be 175 mg/m 2 twice daily (350 mg/m 2 per day) for 5 days. This is the first study to define the MTD of temozolomide administered twice daily and in conjunction with thiotepa, carboplatin and AHCR in patients with recurrent or newly diagnosed malignant brain tumors. In general, the therapy was well tolerated with no toxic deaths. Adverse side effects occurred in o50% of the cohort with the most common side effects consisting of bacteremia, nausea/vomiting, elevated transaminases and decreased performance, supporting previous studies citing the favorable toxicity profile of temozolomide. 9, 13 On the basis of the results of this study, we conclude that increased doses of temozolomide are feasible when given with AHCR. As with many high-dose chemotherapy trials, efficacy of treatment will need to be analyzed in the context of multimodal therapy, but the combination of temozolomide, thiotepa and carboplatin with AHCR may improve survival in patients with recurrent malignant brain tumors, in particular those with highgrade gliomas in second or third complete response and those with minimal residual disease. Following upon these results, a phase II study using temozolomide, thiotepa and carboplatin with AHCR for children with recurrent malignant brain tumors is now being conducted through the Pediatric Blood and Marrow Transplant Consortium.
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